Cathie Wood’s Ark Invest increased its exposure to AI infrastructure, digital platforms, and biotechnology, led by purchases of $25.9M of CoreWeave (CRWV [https://seekingalpha.com/symbol/CRWV]), $24.4M of Meta Platforms (META [https://seekingalpha.com/symbol/META]) and $17.6M of Recursion Pharmaceuticals (RXRX [https://seekingalpha.com/symbol/RXRX]). The firm also bought $16.3M of Cerebras Systems (CBRS [https://seekingalpha.com/symbol/CBRS]) and $9.4M of Rocket Lab (RKLB [https://seekingalpha.com/symbol/RKLB]). In biotechnology, Ark added to its positions in Freenome (FRNM [https://seekingalpha.com/symbol/FRNM]), CRISPR Therapeutics (CRSP [https://seekingalpha.com/symbol/CRSP]), Compass Pathways (CMPS [https://seekingalpha.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.